Trials / Completed
CompletedNCT00956410
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAD106 |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-08-11
- Last updated
- 2020-02-11
Locations
4 sites across 4 countries: France, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00956410. Inclusion in this directory is not an endorsement.